Breaking Finance News

A statement released earlier today by Barclays PLC about Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) bumps the target price to $19.00

Stating a potential upside of 0.61%, Barclays PLC upped the price target of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) to $19.00

Having a price of $11.77, Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) traded 7.27% higher on the day. With the last close up 14.68% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Momenta Pharmaceuticals, Inc. has recorded a 50-day average of $11.92 and a two hundred day average of $11.00. Volume of trade was down over the average, with 235,387 shares of MNTA changing hands under the typical 531,912

Performance Chart

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)

With a total market value of $0, Momenta Pharmaceuticals, Inc. has with a one year low of $7.86 and a one year high of $18.85 .

A total of 9 analysts have released a research note on Momenta Pharmaceuticals, Inc.. Five analysts rating the company a strong buy, one analyst rating the company a buy, three analysts rating the company a hold, one analyst rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $16.33.

More About Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)

Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. It has developed generic version of Lovenox (enoxaparin sodium injection). Its GLATOPA is a generic version of once-daily COPAXONE 20 milligrams/milliliter (mg/mL) indicated for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS), a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. It is developing M923, which is a biosimilar of HUMIRA and M834 as a biosimilar of ORENCIA. Its oncology product candidate Necuparanib, is an oncology product candidate, which have a range of effects on tumor cells and the environment, in which tumor cells grow. It focuses on M281, which is an Anti-FcRn program.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *